UBS Group
GTBP icon

UBS Group’s GT Biopharma GTBP Stock Holding History

UBS Group’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.8K Buy
45,970
+45,969
+4,596,900% +$25.1K ﹤0.01% 7983
2025
Q4 		$1 Sell
1
-2,625
-100% -$1.86K ﹤0.01% 10428
2025
Q3 		$1.54K Sell
2,626
-3,184
-55% -$4.76K ﹤0.01% 9322
2025
Q2 		$20.8K Buy
5,810
+3,251
+127% +$8.4K ﹤0.01% 8405
2025
Q1 		$5.5K Sell
2,559
-2,437
-49% -$5.73K ﹤0.01% 8984
2024
Q4 		$15.2K Buy
4,996
+1,093
+28% +$2.96K ﹤0.01% 8054
2024
Q3 		$9.01K Sell
3,903
-5,078
-57% -$12.1K ﹤0.01% 7806
2024
Q2 		$25.4K Buy
8,981
+7,958
+778% +$28.5K ﹤0.01% 7148
2024
Q1 		$4.53K Buy
1,023
+536
+110% +$2.83K ﹤0.01% 7614
2023
Q4 		$3.72K Buy
487
+195
+67% +$1.43K ﹤0.01% 7937
2023
Q3 		$2.11K Buy
292
+191
+189% +$1.58K ﹤0.01% 7767
2023
Q2 		$946 Sell
101
-159
-61% -$1.65K ﹤0.01% 8060
2023
Q1 		$4.29K Buy
260
+143
+122% +$3.28K ﹤0.01% 8208
2022
Q4 		$3.13K Buy
117
+11
+10% +$549 ﹤0.01% 9559
2022
Q3 		$5K Buy
106
+2
+2% +$153 ﹤0.01% 9195
2022
Q2 		$9K Sell
104
-43
-29% -$3.26K ﹤0.01% 8133
2022
Q1 		$13K Sell
147
-234
-61% -$20.6K ﹤0.01% 8048
2021
Q4 		$34K Buy
381
+222
+140% +$33.2K ﹤0.01% 7262
2021
Q3 		$32K Buy
159
+56
+54% +$16.9K ﹤0.01% 6692
2021
Q2 		$48K Sell
103
-28
-21% -$11.6K ﹤0.01% 6472
2021
Q1 		$27K Buy
+131
New +$22.9K ﹤0.01% 7094

Other funds holding GTBP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
I
INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group's GTBP Position: Q1 2026 in Review

UBS Group increased its GT Biopharma (GTBP) stake by 4,596,900% in Q1 2026, buying an estimated $25.1K and bringing the position to 45,970 shares worth $18.8K. The position accounts for ﹤0.01% of the portfolio, ranked #7983.

UBS Group first reported a position in GTBP in Q1 2021 and has held it in 21 quarters since. The position peaked at $48K in Q2 2021. 42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

  • UBS Group held 45,970 shares of GT Biopharma worth $18.8K as of Q1 2026.
  • UBS Group bought 45,969 GT Biopharma shares in Q1 2026, an estimated $25.1K.
  • GT Biopharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7983 holding.
  • UBS Group first reported a position in GT Biopharma in Q1 2021 and has held it in 21 quarters since.
  • UBS Group's GT Biopharma position peaked at $48K in Q2 2021.
  • 42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.